Delcath Systems announces investigator-initiated CHOPIN Phase 2 presentation

Delcath Systems (DCTH) “announced the acceptance of an oral presentation on results from the investigator-initiated CHOPIN randomized Phase 2 trial at the 2025 European Society for Medical Oncology, ESMO, Annual Congress. Principal Investigator Ellen Kapiteijn, MD, from Leiden University Medical Center’s Department of Medical Oncology, will present data evaluating the safety, tolerability, and efficacy of sequencing systemic ipilimumab and nivolumab with Delcath’s CHEMOSAT(R) Hepatic Delivery System for percutaneous hepatic perfusion with melphalan in patients with metastatic uveal melanoma.”